Chris is a founding partner of Brandon Capital Partners and Chief Executive Officer of Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund). Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies.

Chris was previously the Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia.  Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd. Chris has international experience working for the business development group of Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG (now Bayer).

Chris is currently a director of; Azura Ophthalmics, Certa Therapeutics, EBR Systems (ASX:EBR), Foray Therapeutics, Pathios Therapeutics and PolyActiva. He is also an advisory board member for The WILD Program. Chris holds a number of industry board and representative roles.

Chris has a Bachelor of Science (Honours) from The University of Melbourne and a PhD in Endocrinology and Physiology from The University of Melbourne.